이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Invivyd 과거 수익 실적

과거 기준 확인 0/6

Invivyd의 수입은 연평균 -0.04%의 비율로 감소해 온 반면, Biotechs 산업의 수입은 연간 증가했습니다(15.5%).

주요 정보

-0.04%

수익 성장률

116.6%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	n/a
자기자본 수익률	-115.9%
순이익	n/a
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

업데이트 없음

Recent updates

We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow

Feb 19

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

Feb 16

Adagio Therapeutics: The Market Is Too Crowded For Its Lead Drug Candidate

Nov 29

수익 및 비용 분석

Invivyd 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGM:IVVD 수익, 비용 및 수입 (USD Millions )
날짜	수익	G+A 비용	R&D 비용
31 Mar 24	-207	53	163
31 Dec 23	-199	49	159
30 Sep 23	-170	45	116
30 Jun 23	-175	45	121
31 Mar 23	-176	49	114
31 Dec 22	-241	47	179
30 Sep 22	-280	51	228
30 Jun 22	-295	49	243
31 Mar 22	-289	42	241
31 Dec 21	-227	37	183
30 Sep 21	-208	26	145

양질의 수익: IVVD 은(는) 현재 수익성이 없습니다.

이익 마진 증가: IVVD 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: IVVD 은(는) 수익성이 없으며 지난 5년 동안 연간 0.04% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 IVVD 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: IVVD 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -14.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: IVVD 현재 수익성이 없기 때문에 마이너스 자본 수익률( -115.87% )을 갖습니다.

Invivyd 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Recent updates

Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

Invivyd, Inc. Announces Management Changes

Invivyd, Inc. Elects Two New Independent Members to its Board of Directors

Forecast to breakeven in 2026

Invivyd, Inc. to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Invivyd, Inc., Annual General Meeting, May 21, 2024

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Announces CEO Changes

Invivyd, Inc. Announces CEO Transition

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates fall by 13%

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Forecast breakeven date moved forward to 2025

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Consensus revenue estimates increase by 64%

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

New minor risk - Shareholder dilution

Forecast to breakeven in 2026

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19

Invivyd, Inc. Appoints William Duke as Chief Financial Officer

Invivyd, Inc. Appoints Sara Cotter to Board of Directors

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd, Inc. Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Invivyd, Inc. Announces Executive Changes

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Invivyd, Inc

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

Less than half of directors are independent

Invivyd Announces Board Changes

Invivyd, Inc. Announces Executive Changes

Invivyd appoints interim CFO, makes headcount changes

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in Vitro Data Against Omicron Variants

Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies

Adagio Therapeutics GAAP EPS of -$0.47

We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate

Adagio Therapeutics, Inc. Appoints David Hering Permanent Chief Executive Officer

Less than half of directors are independent

Adagio names David Hering as permanent CEO and Director

Howard Mayer, M.D. Notifies Adagio Therapeutics, Inc. of His Decision to Resign from the Board of Directors

Adagio Therapeutics, Inc.(NasdaqGM:ADGI) dropped from Russell 2000 Growth Index

Adagio Therapeutics, Inc. Elects Class I Directors

Adagio Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Adagio Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

No longer forecast to breakeven

Mithril Capital Provides Information to Shareholders of Adagio Therapeutics

Adagio Therapeutics, Inc. Provides Update on Timing of Adintrevimab EUA Request

No longer forecast to breakeven

No longer forecast to breakeven

Mithril Capital Management Communicates with Adagio Therapeutics

Adagio Therapeutics, Inc. Announces Executive Changes, Effective March 25, 2022

Adagio's Round Trip

Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates

Adagio Therapeutics, Inc. Announces Executive Changes

We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

Adagio Therapeutics, Inc. Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron

Adagio Therapeutics: The Market Is Too Crowded For Its Lead Drug Candidate

Adagio Therapeutics, Inc. Reports Updates on Its Lead Covid-19 Antibody Program, ADG20

Adagio Therapeutics, Inc. Announces the Independent Data Monitoring Committee (IDMC) for the EVADE Phase 2/3 Trial of ADG20 for the Prevention of COVID-19

Adagio Therapeutics, Inc. has completed an IPO in the amount of $309.4 million.

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률